Antibody humanization by structure-based computational protein design

Antibodies derived from non-human sources must be modified for therapeutic use so as to mitigate undesirable immune responses. While complementarity-determining region (CDR) grafting-based humanization techniques have been successfully applied in many cases, it remains challenging to maintain the desired stability and antigen binding affinity upon grafting. We developed an alternative humanization approach called CoDAH (“Computationally-Driven Antibody Humanization”) in which computational protein design methods directly select sets of amino acids to incorporate from human germline sequences to increase humanness while maintaining structural stability. Retrospective studies show that CoDAH is able to identify variants deemed beneficial according to both humanness and structural stability criteria, even for targets lacking crystal structures. Prospective application to TZ47, a murine anti-human B7H6 antibody, demonstrates the approach. Four diverse humanized variants were designed, and all possible unique VH/VL combinations were produced as full-length IgG1 antibodies. Soluble and cell surface expressed antigen binding assays showed that 75% (6 of 8) of the computationally designed VH/VL variants were successfully expressed and competed with the murine TZ47 for binding to B7H6 antigen. Furthermore, 4 of the 6 bound with an estimated KD within an order of magnitude of the original TZ47 antibody. In contrast, a traditional CDR-grafted variant could not be expressed. These results suggest that the computational protein design approach described here can be used to efficiently generate functional humanized antibodies and provide humanized templates for further affinity maturation.

[1]  Roland L. Dunbrack,et al.  A new clustering of antibody CDR loop conformations. , 2011, Journal of molecular biology.

[2]  Ming Lei,et al.  Frontier of therapeutic antibody discovery: The challenges and how to face them. , 2012, World journal of biological chemistry.

[3]  L. Presta,et al.  Antibody Humanization Using Monovalent Phage Display* , 1997, The Journal of Biological Chemistry.

[4]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[5]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[6]  Ming-Ru Wu,et al.  An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo , 2012, The Journal of Immunology.

[7]  S. Batra,et al.  Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti‐tag‐72 single‐chain Fvs , 2001, International journal of cancer.

[8]  T. Ohta,et al.  Population Biology of Antigen Presentation by MHC Class I Molecules , 1996, Science.

[9]  Chris Bailey-Kellogg,et al.  A divide‐and‐conquer approach to determine the Pareto frontier for optimization of protein engineering experiments , 2012, Proteins.

[10]  Noreen R. Gonzales,et al.  SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. , 2004, Molecular immunology.

[11]  Andrew C. R. Martin,et al.  The humanness of macaque antibody sequences. , 2010, Journal of molecular biology.

[12]  W. C. Still,et al.  The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii , 1997 .

[13]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[14]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[15]  C. Deane,et al.  ABangle: characterising the VH-VL orientation in antibodies. , 2013, Protein engineering, design & selection : PEDS.

[16]  D. Baker,et al.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.

[17]  Amy C. Anderson,et al.  Computational structure-based redesign of enzyme activity , 2009, Proceedings of the National Academy of Sciences.

[18]  A. Younes,et al.  A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma , 2015, British journal of haematology.

[19]  Vibha Jawa,et al.  T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.

[20]  Bruce Randall Donald,et al.  Protein Design Using Continuous Rotamers , 2012, PLoS Comput. Biol..

[21]  A. Lesk,et al.  Conformations of immunoglobulin hypervariable regions , 1989, Nature.

[22]  H. Steven Wiley,et al.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library , 2003, Nature Biotechnology.

[23]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[24]  C. Deane,et al.  CODA: A combined algorithm for predicting the structurally variable regions of protein models , 2001, Protein science : a publication of the Protein Society.

[25]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[26]  P. Carter Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[27]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[28]  Paolo Marcatili,et al.  Prediction of site-specific interactions in antibody-antigen complexes: the proABC method and server , 2013, Bioinform..

[29]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[30]  E. Reinherz,et al.  Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms. , 2003, Journal of molecular biology.

[31]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[32]  Jeffrey J. Gray,et al.  Toward high‐resolution homology modeling of antibody Fv regions and application to antibody–antigen docking , 2009, Proteins.

[33]  Chris Bailey-Kellogg,et al.  Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate , 2014, Cellular and Molecular Life Sciences.

[34]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor VJ and VDJrearrangement analysis , 2004, Nucleic Acids Res..

[35]  Brian D. Weitzner,et al.  Blind prediction performance of RosettaAntibody 3.0: Grafting, relaxation, kinematic loop modeling, and full CDR optimization , 2014, Proteins.

[36]  Charlotte M Deane,et al.  Predicting antibody complementarity determining region structures without classification. , 2011, Molecular bioSystems.

[37]  Chris Bailey-Kellogg,et al.  Mapping the Pareto Optimal Design Space for a Functionally Deimmunized Biotherapeutic Candidate , 2015, PLoS Comput. Biol..

[38]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[39]  Yoonjoo Choi,et al.  FREAD revisited: Accurate loop structure prediction using a database search algorithm , 2010, Proteins.

[40]  Benjamin D. Sellers,et al.  Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains. , 2009, Journal of molecular biology.

[41]  Yanay Ofran,et al.  Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure , 2012, Nucleic Acids Res..

[42]  Chris Bailey-Kellogg,et al.  Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.

[43]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[44]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[45]  Ida Retter,et al.  VBASE2, an integrative V gene database , 2004, Nucleic Acids Res..

[46]  Chris Bailey-Kellogg,et al.  Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loads , 2015, Biotechnology and bioengineering.

[47]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[48]  N. Lonberg,et al.  Human Monoclonal Antibodies from Transgenic Mice , 2008, Handbook of experimental pharmacology.

[49]  Donald Hilvert,et al.  De novo enzymes by computational design. , 2013, Current opinion in chemical biology.

[50]  Uwe T Bornscheuer,et al.  Finding better protein engineering strategies. , 2009, Nature chemical biology.

[51]  M. Berger,et al.  Human antibodies for immunotherapy development generated via a human B‐cell hybridoma technology , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Sebastian Kelm,et al.  Fragment‐based modeling of membrane protein loops: Successes, failures, and prospects for the future , 2014, Proteins.

[53]  Jan Brezovsky,et al.  Computational tools for designing and engineering enzymes. , 2014, Current opinion in chemical biology.

[54]  François Ehrenmann,et al.  IMGT/3Dstructure-DB: querying the IMGT database for 3D structures in immunology and immunoinformatics (IG or antibodies, TR, MH, RPI, and FPIA). , 2011, Cold Spring Harbor protocols.

[55]  Herren Wu,et al.  Antibody humanization by framework shuffling. , 2005, Methods.

[56]  R. Goldstein Efficient rotamer elimination applied to protein side-chains and related spin glasses. , 1994, Biophysical journal.

[57]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[58]  Paolo Marcatili,et al.  PIGS: automatic prediction of antibody structures , 2008, Bioinform..

[59]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[60]  Anna Tramontano,et al.  Tabhu: tools for antibody humanization , 2015, Bioinform..

[61]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[62]  A. Adler,et al.  Monoclonal antibody humanness score and its applications , 2013, BMC Biotechnology.

[63]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[64]  A R Rees,et al.  Humanization of murine monoclonal antibodies through variable domain resurfacing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Dennis CDR Repair: A Novel Approach to Antibody Humanization , 2010 .

[66]  Andrew C. R. Martin,et al.  Analyzing the "degree of humanness" of antibody sequences. , 2007, Journal of molecular biology.

[67]  Haruki Nakamura,et al.  High‐resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations , 2014, Proteins.

[68]  B. Bogen,et al.  Review: To What Extent are T Cells Tolerant to Immunoglobulin Variable Regions? , 2009, Scandinavian journal of immunology.

[69]  David Baker,et al.  Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.

[70]  Andrew C. R. Martin,et al.  Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. , 2008, Molecular immunology.

[71]  N. Bradley,et al.  A novel platform to produce human monoclonal antibodies , 2011, mAbs.

[72]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[73]  A. Speak,et al.  Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery , 2014, Nature Biotechnology.

[74]  J. Osbourn,et al.  From rodent reagents to human therapeutics using antibody guided selection. , 2005, Methods.

[75]  Roland L. Dunbrack,et al.  proteins STRUCTURE O FUNCTION O BIOINFORMATICS Improved prediction of protein side-chain conformations with SCWRL4 , 2022 .

[76]  G. A. Lazar,et al.  A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.

[77]  G. Alter,et al.  Highly parallel characterization of IgG Fc binding interactions , 2014, mAbs.

[78]  Richard Friesner,et al.  Antibody structure determination using a combination of homology modeling, energy‐based refinement, and loop prediction , 2014, Proteins.

[79]  J. C. Almagro,et al.  Use of human germline genes in a CDR homology-based approach to antibody humanization. , 2005, Methods.

[80]  S. Farajnia,et al.  Antibody humanization methods – a review and update , 2013, Biotechnology & genetic engineering reviews.